Back

Unlocking the role of SH3PXD2B in epithelial-to-mesenchymal transition driving Breast Cancer Lung Metastasis

Das, S.; Khilwani, R.; Singh, s.

2024-10-18 systems biology
10.1101/2024.10.16.618596 bioRxiv
Show abstract

Despite advancements in breast cancer treatment, metastasis remains a significant challenge, contributing to high mortality rates. This study investigates the mechanisms underlying breast cancer lung metastasis, with a particular emphasis on the role of SH3PXD2B in driving epithelial-to-mesenchymal transition. Here, we analyzed RNA sequencing data from CCLE and TCGA databases and characterized that SH3PXD2B expression is elevated in breast cancer (BC) and lung cancer (LC) tissues compared to non-transformed tissues. Bioinformatics analysis revealed that SH3PXD2B regulates several cellular processes and is associated with poor prognosis in breast cancer (BRCA) and lung adenocarcinoma (LUAD) patients. Functional experiments underscore that the upregulation of SH3PXD2B promoted BC and LC cell migration in vitro; however, its knockdown inhibited the effect. Mechanistically, the mass spectrometry analysis was utilized to pull down interacting partners of SH3PXD2B, and the findings were substantiated by immunoblotting. Additionally, our findings on immunofluorescence and gene expression analysis demonstrated the additive role of SH3PXD2B and migratory proteins in promoting breast cancer progression. Further, we performed bioluminescent IVIS imaging analysis to trace the metastatic spread of MDA-MB-468 cells and observed strong signals and a high degree of dissemination to distant organs. Collectively, our results highlight the importance of SH3 domains in aggravating breast transformation, which can therefore serve as a promising therapeutic strategy in counteracting breast-related malignancy. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=156 SRC="FIGDIR/small/618596v1_ufig1.gif" ALT="Figure 1"> View larger version (56K): org.highwire.dtl.DTLVardef@1fe7792org.highwire.dtl.DTLVardef@15c4481org.highwire.dtl.DTLVardef@9575f4org.highwire.dtl.DTLVardef@72ea93_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Frontiers in Oncology
103 papers in training set
Top 0.1%
18.3%
2
Translational Oncology
21 papers in training set
Top 0.1%
11.8%
3
ACS Omega
105 papers in training set
Top 0.1%
6.2%
4
Theranostics
37 papers in training set
Top 0.1%
4.8%
5
Scientific Reports
3612 papers in training set
Top 23%
4.3%
6
eLife
5828 papers in training set
Top 31%
3.5%
7
iScience
1154 papers in training set
Top 5%
3.5%
50% of probability mass above
8
International Journal of Cancer
49 papers in training set
Top 0.3%
3.4%
9
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
2.6%
10
Biomedicines
67 papers in training set
Top 0.6%
2.4%
11
Cells
249 papers in training set
Top 2%
1.9%
12
PLOS ONE
5266 papers in training set
Top 46%
1.9%
13
Heliyon
152 papers in training set
Top 3%
1.9%
14
Cancers
213 papers in training set
Top 3%
1.9%
15
Molecular Cancer Research
49 papers in training set
Top 0.7%
1.7%
16
OncoImmunology
24 papers in training set
Top 0.4%
1.7%
17
BMC Cancer
67 papers in training set
Top 1%
1.7%
18
Cell Communication and Signaling
51 papers in training set
Top 0.7%
1.4%
19
Cell Proliferation
12 papers in training set
Top 0.2%
1.1%
20
International Journal of Molecular Sciences
494 papers in training set
Top 12%
1.1%
21
Communications Biology
993 papers in training set
Top 27%
1.0%
22
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
26 papers in training set
Top 0.9%
0.8%
23
Cell Death & Disease
126 papers in training set
Top 3%
0.8%
24
Biomolecules
100 papers in training set
Top 3%
0.8%
25
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 5%
0.8%
26
Frontiers in Molecular Biosciences
102 papers in training set
Top 2%
0.8%
27
Journal of Cellular and Molecular Medicine
20 papers in training set
Top 0.7%
0.8%
28
Computational and Structural Biotechnology Journal
242 papers in training set
Top 8%
0.6%
29
Molecular Oncology
55 papers in training set
Top 2%
0.6%
30
Nature Communications
5641 papers in training set
Top 60%
0.6%